Overview
Nausea and vomiting in pregnancy (NVP), commonly known as "morning sickness", affects 50-90% of pregnant women.
Symptoms can occur at any time of the day; therefore, the term “morning sickness” is incorrect, with 95% of patients have symptoms before and after midday and 4% experience symptoms only in the morning.
Severity of NVP during the 1st trimester can be assessed using the Pregnancy-Unique Quantification of Emesis (PUQE) score, with he scores obtained are associated with quality-of-life measurements.
Phamacotherapy in NVP includes Pyridoxine with or without Doxylamine, antihistamines, phenothiazines, and Metoclopramide.
For further information regarding the management of Nausea & Vomiting in Pregnancy, please refer to Disease Algorithm for the Treatment Guideline.
Symptoms can occur at any time of the day; therefore, the term “morning sickness” is incorrect, with 95% of patients have symptoms before and after midday and 4% experience symptoms only in the morning.
Severity of NVP during the 1st trimester can be assessed using the Pregnancy-Unique Quantification of Emesis (PUQE) score, with he scores obtained are associated with quality-of-life measurements.
Phamacotherapy in NVP includes Pyridoxine with or without Doxylamine, antihistamines, phenothiazines, and Metoclopramide.
For further information regarding the management of Nausea & Vomiting in Pregnancy, please refer to Disease Algorithm for the Treatment Guideline.
